Newlamon Welcomes Dr. Amelia Hartley to Academic Advisory Board

BRISBANE, Australia – Newlamon, the New Zealand-based premium nutrition brand and pioneer of the "Stage-Specific Immunity" concept, has announced the appointment of Dr. Amelia Hartley, tenured professor at the Queensland Brain Institute (QBI), University of Queensland, as Academic Advisor for its Zhenzhigao Series. Dr. Hartley and her research team will provide scientific guidance for the development and clinical validation of the brand's SN-2 Algal DHA products.

A Leading Authority in Early Brain Development Nutrition

Dr. Amelia Hartley is an internationally recognized expert in infant and childhood brain development nutrition, with research spanning cognitive neuroscience and the role of DHA in synaptic plasticity. She earned her Ph.D. in Neuroscience from the University of Melbourne in 2008 and completed her postdoctoral research at the University of Cambridge, focusing on how early-life nutrition shapes neural circuitry. In 2015, she joined the Queensland Brain Institute at the University of Queensland, where she established the Early Brain Development and Nutrition Science Laboratory.

Her laboratory has systematically investigated the mechanisms by which docosahexaenoic acid (DHA) and neuropeptides contribute to synaptic plasticity and memory formation. Dr. Hartley has demonstrated that DHA is a critical structural component of neuronal membranes in the cerebral cortex, playing an essential role in both foundational neural development and higher cognitive functions. These findings were published in a 2021 issue of Nature Neuroscience and subsequently recommended by the International Union of Nutritional Sciences (IUNS) as a key theoretical foundation for infant formula research.

Advancing Precision Nutrition Through SN-2 DHA Research

Dr. Hartley's research has provided critical insights into the structure-function relationship of DHA. Her work confirms that over 52.63% of DHA in human breast milk naturally exists at the SN-2 position of the triglyceride molecule. This specific molecular configuration significantly enhances DHA accumulation in the cerebral cortex compared to randomly distributed DHA, as demonstrated in her laboratory's animal studies.

As Academic Advisor for the Newlamon Series, Dr. Hartley has been deeply involved in two key areas: the precise SN-2 positional simulation of breast milk DHA structure, and the clinical validation of micro-suspension technology to optimize DHA bioavailability. Her contributions have provided the scientific foundation for the formulation and efficacy assessment of Newlamon's SN-2 Algal DHA products.

Honors and Professional Affiliations

Dr. Hartley serves as the Asia-Pacific Regional Director of the International Society for Brain Nutrition (ISBNA) and is a senior member of the Australian Neuroscience Society (ANS). In 2024, she was named "Outstanding Researcher of the Year" by the journal Frontiers in Neuroscience and Nutrition.

A Shared Commitment to Precision Nutrition

Newlamon has built its reputation on the principle that "true growth is not about filling, but about activating the body's innate potential." The brand's Newlamon Series, featuring SN-2 Algal DHA with 80% purity, embodies this philosophy by delivering nutrition in a form most naturally aligned with human biology.

"The brain's development is not a coincidence—it is the cumulative result of every precise nutrient delivered at the right time," said Dr. Hartley. "Newlamon's commitment to SN-2 positional specificity and rigorous clinical validation aligns with the highest standards of evidence-based nutrition science. I am honored to support this work."